title: Ii chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes.
abstract: Major histocompatibility complex class II molecules are synthesized as a nonameric complex consisting of three alpha beta dimers associated with a trimer of invariant (Ii) chains. After exiting the TGN, a targeting signal in the Ii chain cytoplasmic domain directs the complex to endosomes where Ii chain is proteolytically processed and removed, allowing class II molecules to bind antigenic peptides before reaching the cell surface. Ii chain dissociation and peptide binding are thought to occur in one or more postendosomal sites related either to endosomes (designated CIIV) or to lysosomes (designated MIIC). We now find that in addition to initially targeting alpha beta dimers to endosomes, Ii chain regulates the subsequent transport of class II molecules. Under normal conditions, murine A20 B cells transport all of their newly synthesized class II I-A(b) alpha beta dimers to the plasma membrane with little if any reaching lysosomal compartments. Inhibition of Ii processing by the cysteine/serine protease inhibitor leupeptin, however, blocked transport to the cell surface and caused a dramatic but selective accumulation of I-A(b) class II molecules in lysosomes. In leupeptin, I-A(b) dimers formed stable complexes with a 10-kD NH2-terminal Ii chain fragment (Ii-p10), normally a transient intermediate in Ii chain processing. Upon removal of leupeptin, Ii-p10 was degraded and released, I-A(b) dimers bound antigenic peptides, and the peptide-loaded dimers were transported slowly from lysosomes to the plasma membrane. Our results suggest that alterations in the rate or efficiency of Ii chain processing can alter the postendosomal sorting of class II molecules, resulting in the increased accumulation of alpha beta dimers in lysosome-like MIIC. Thus, simple differences in Ii chain processing may account for the highly variable amounts of class II found in lysosomal compartments of different cell types or at different developmental stages.
authors.affiliation: Institut Curie, Section de Recherche Institut National de la Santé et de la Recherche Médicale CJF-95.01, Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Brachet
authors.forename: G
authors.initials: G
authors.lastname: Raposo
authors.forename: S
authors.initials: S
authors.lastname: Amigorena
authors.forename: I
authors.initials: I
authors.lastname: Mellman
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D001692:Biological Transport / Q000502:physiology; D002451:Cell Compartmentation / Q000502:physiology; D002462:Cell Membrane / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D019281:Dimerization; D004586:Electrophoresis / Q000379:methods; D000949:Histocompatibility Antigens Class II / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D007976:Leupeptins / Q000494:pharmacology; D008223:Lymphoma; D008247:Lysosomes / Q000737:chemistry / Q000378:metabolism* / Q000648:ultrastructure; D051379:Mice; D016253:Microscopy, Immunoelectron; D017434:Protein Structure, Tertiary; D014407:Tumor Cells, Cultured / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure
chemical_list: D000954:Antigens, Surface; D000949:Histocompatibility Antigens Class II; D007976:Leupeptins; C032854:leupeptin